

Cover Story
Regulatory News
By Jacquelyn Cobb and Paul Goldberg
Can a single drug replace a long-established curative, albeit brutal, regimen of chemotherapy, radiation, and surgery?
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval

















